Pharmacy Regulation Should Remain State Function, Groups Tell Sen. Bond
Executive Summary
The federal government does not need to expand its role in pharmacy oversight in the wake of an incident of product tampering by a Kansas City pharmacist, pharmacy associations said in a letter to Sen. Christopher Bond (R-Mo.).
You may also be interested in...
Lilly Finds IMS Data Solution, Uncovers Gemzar Dilution In Kansas City
Lilly's decision to use IMS Health's wholesale tracking data in the Kansas City area for oncology sales rep bonuses helped lead to the discovery that an area pharmacist appeared to be diluting chemotherapy drugs.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials